Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.